If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Nemera’s preservative-free multidose eye dropper Novelia approved for Santen’s Cosopt for Glaucoma treatments

    Quick Contact
    Nemera’s preservative-free multidose eye dropper Novelia approved for Santen’s Cosopt for Glaucoma treatments
    Europe, Asia, East Asia, China, Health, Pharmaceuticals, Primary Packaging, Bottles, Dispensing Closures, Bulbs, Pipettes, Droppers, Shows, Associations, Media, Packaging Trade Shows, Events

    Nemera’s multidose eye dropper Novelia® has been approved for the preservative-free formulation Cosopt iMulti®

    There is an innovation in glaucoma management by providing preservative-free medicines in multi-dose bottles to allow for effective and convenient, 24-hour intraocular pressure (IOP) control to glaucoma patients aged 18 or over.

    “We are delighted to launch preservative-free multi-dose formulations of these glaucoma therapies in Europe,” said Luis Iglesias, Corporate Officer and Head of EMEA, Santen. “By providing highly effective and well-tolerated, preservative-free medicines, with the option for multi-dose bottles, we hope to empower patients in their daily lives and improve the management of their condition.”

    “Patient adherence is the key for success for all treatments, especially silent chronic ophthalmic diseases. This is why, at Nemera, we developed an innovative system combining all patient needs: a safe preservative-free multi-dose bottle with a blue tip that makes consistent drops one by one” commented Fanny Sellier, Global Category Manager for Ophthalmic Products, Nemera.

    The importance of preservative-free

    The European Medicines Agency (EMA) outlines that preservatives should be avoided in patients who are on long-term treatment, or do not tolerate preserved eye drops.

    Switching from preserved to preservative-free topical ocular medications can diminish the harmful effects caused by preservatives. For example, switching to Cosopt preservative-free improved local ocular tolerability for 85% of patients compared with their previous preserved medication

    Key benefits of Novelia

    • 100% controlled and safe thanks to its patented PureFlow® Technology
    • Works with high viscosity suspensions, emulsions and solutions up to 1500cps
    • User-friendly and intuitive: easy eye targeting thanks to its blue tip feature, as easy to use as any standard eyedropper
    • One drop at a time into the patient’s eye
    • Calibrated drops providing a precise dose for a better treatment adherence

    Novelia will also be shown at differents events in the next months: Interphex, ARVO, FCE Pharma, CPhI China and CPhI Worldwide.

    See also

    Nemera's RetroNose enhances therapeutic efficacy of nasal treatments

    The number of applications through the nasal route is expanding, either for local treatments (e.g. chronic rhinosinusitis) or for systemic treatments (e.g. migraine, etc.). The clinical efficacy of a nasal treatment depends on how it is deposited in the nose, because the pharmaceutical target (local, systemic, brain) is directly related to a specific nasal anatomical site. That’s why Nemera has collaborated with CEPR to develop a different and portable delivery technology called RetroNose for a better drug deposition in the distal region of the nose, without lung deposition.

    e-Novelia wins the ‘Excellence in Pharma: Drug Delivery Devices’ award at CPhI Worldwide 2018

    On October 9th, during the CPhI Pharma Awards Gala, e-Novelia®, Nemera’s electronic add-on for ophthalmic droppers, was celebrated as the best-in-class innovation displayed at the show for “Excellence in Pharma: Drug Delivery Devices”. e-Novelia®, Nemera’s smart ophthalmic add-on, has been designed to make patients’ life easier, by offering increased comfort and optimized adherence to their treatments.

    Safelia 1ml and 2.25ml autoinjectors designed to be patient and syringe friendly

    Nemera’s new generation 2-step autoinjector platforms are suitable for fluid to highly viscous injections. Safelia® has been designed to ease patient self-injection experience and to deliver even the most challenging drugs (viscous formulations up to several Centipoise, sustain released, concentrated, fragile and shear sensitive formulations, either in subcutaneous or intramuscular layers, on two platforms: up to 1ml or up to 2.25ml delivery).

    • Brand Launch
    • English
    • Modified 15 Apr 2019
    • Hits 2851
    Sun-Rain
    APG
    Epopack